Zalicus to Present Data on Oncology Programs at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Meeting
- Systematic Combination Studies Reveal Patterns of Sensitivity and Resistance -
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 18, 2010 - Zalicus Inc. (NASDAQ: ZLCS) presented data today on its discovery of novel synergistic drug combinations for the treatment of cancer at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Meeting in Berlin, Germany on November 18, 2010. In a poster presentation entitled “Identification of synergistic drugs using combination high-throughput screening (cHTS) and breadth of activity in diverse cancer cell networks,” Richard Rickles, Ph.D., Zalicus's Director of Oncology Research demonstrated that systematic combination studies using the Zalicus combination high-throughput screening (cHTS) technology can reveal patterns of chemotherapeutic sensitivity and resistance to identify potentially responsive patient populations.
Dr. Rickles evaluated signaling pathways that contain a number of important anti-cancer therapeutic targets, such as P13K and RAS, across a panel of cancer cell lines. His results indicate that simple pathway mutational analysis is insufficient to predict the outcome of concurrent inhibition while systematic combination studies using combination high-throughput screening technology can reveal unexpected patterns of sensitivity and resistance.
“These data, which were generated with our combination high-throughput screening (cHTS™) technology, support the rationale that employing a systematic approach to the discovery of novel targets and pathway interactions specific to cancer biology will lead toward development of more selective and efficacious combination therapeutics for a wide variety of cancers,” commented Mark H.N. Corrigan, M.D., President and CEO of Zalicus Inc. ”Zalicus is continuing to leverage the power of its proprietary cHTS technology through research collaborations with biopharmaceutical companies such as our ongoing oncology research collaboration with Novartis."
Zalicus Inc. (NASDAQ: ZLCS) is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases. Zalicus applies its selective ion-channel modulation platform and its combination high throughput screening capabilities to discover innovative therapeutics for itself and its collaborators in the areas of pain, inflammation, oncology and infectious disease. To learn more about Zalicus, please visit www.zalicus.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning Zalicus, Zalicus' combination drug discovery technology, cHTS, and its other business plans. These forward-looking statements about future expectations, plans, objectives and prospects of Zalicus may be identified by words like "believe," "expect," "may," "will," "should," "seek," “plan” or “could” and similar expressions and involve significant risks, uncertainties and assumptions, including risks related to the development and regulatory approval of Zalicus's product candidates, the unproven nature of the Zalicus drug discovery technologies, and those other risks that can be found in the "Risk Factors" section of Zalicus's annual report on Form 10-K on file with the Securities and Exchange Commission and the other reports that Zalicus periodically files with the Securities and Exchange Commission. Actual results may differ materially from those Zalicus contemplated by these forward-looking statements. These forward looking statements reflect management's current views and Zalicus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release except as required by law.
(c) 2010 Zalicus Inc. All rights reserved.
Posted: November 2010